Skip to main content
Equibles

John B. Henneman, III

Board Member

Anika Therapeutics, Inc. (ANIK)

Chairman

Anika Therapeutics, Inc. (ANIK)

Equibles does not estimate personal net worth.

Get an email with a short summary when Anika Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ANIK alerts

About John B. Henneman, III

John B. Henneman, III is recorded as Board Member at Anika Therapeutics, Inc. (ANIK) since June 18, 2026 and Chairman at Anika Therapeutics, Inc. (ANIK) since February 24, 2024. Anika Therapeutics, Inc. reported in an 8-K filed June 23, 2026 that John B. Henneman, III was appointed Class III director, effective June 18, 2026. Anika Therapeutics, Inc. reported in an 8-K filed February 26, 2024 that John B. Henneman, III was appointed Chair of the Board, effective February 24, 2024. Anika Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Anika Therapeutics, Inc. includes Cheryl Blanchard (CEO and Board Member), Stephen (Steve) Griffin (CEO and Board Member), Stephen D. Griffin (CEO, CFO and Board Member) and 7 others.

“As a result of this vote, Mr. Fischetti, Mr. Henneman and Mr. Griffin were elected as Class III directors to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal.”
Anika Therapeutics, Inc. Form 8-K, filed June 23, 2026 · Read the filing
“John B. Henneman, III, an independent director of the Company's Board since 2020, has been appointed Chair of the Board, effective immediately.”
Anika Therapeutics, Inc. Form 8-K, filed February 26, 2024 · Read the filing

Affiliation history

Company network

Anika Therapeutics, Inc.

ANIK

Current role

Drug Manufacturers - Specialty & Generic · Healthcare

Board Member, Chairman

2024-02-24–present

Leadership on record at Anika Therapeutics, Inc.

Recent activity